Intraocular Properties of a Repository Urokinase Receptor Antagonist Å36 Peptide in Rabbits

REFERENCES

• The Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–572.
   PubMedGoogle Scholar
• Age-Related Eye Disease Study Research Group. Potential public health impact of age-related eye disease study results: AREDS report No. 11. Arch Ophthalmol. 2003;121:1621–1624.
   PubMedGoogle Scholar
• Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Opthtalmol. 2004;137:496–503.
   PubMed Web of Science ®Google Scholar
• Gass JD. Biomicroscopic and histopathologic consideration regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol. 1994;118:285–289.
   PubMed Web of Science ®Google Scholar
• Submacular Surgery Trials Research Group. Histopathology and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions. Report No. 7. Arch Ophthalmol. 2005;123:914–921.
   PubMedGoogle Scholar
• Macular Photocoagulation Study Group. Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration. Arch Ophthalmol. 1996;114:400–412.
   PubMed Web of Science ®Google Scholar
• Sharma S, Bakal J, Oliver-Fernandez A, et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration: Results of an effectiveness study. Arch Ophthalmol. 2004;122:853–856.
   PubMedGoogle Scholar
• Sadda SR, Pieramici DJ, Marsh MJ, et al. Submacular surgery trials pilot study investigators. Changes in lesion size after submacular surgery for subfoveal choroidal neovascularization in the submacular surgery trials pilot study. Retina. 2004;24:888–899.
   PubMed Web of Science ®Google Scholar
• American Academy of Ophthalmology. Macular translocation. Ophthalmology. 2000;107:1015–1018.
   PubMed Web of Science ®Google Scholar
• Armbrecht AM, Aspinal PA, Dhillon B. A prospective study of visual function and quality of life following PDT in patents with wet age related macular degeneration. Br J Ophthalmol. 2004;88:1270–1273.
   PubMed Web of Science ®Google Scholar
• TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials—Tap report. Arch Ophthalmol. 1999;117:1329–1345.
   PubMedGoogle Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–2816.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431.
   PubMed Web of Science ®Google Scholar
• Spaide RF, Laud K, Fine HF, et al. Intrravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383–390.
   PubMed Web of Science ®Google Scholar
• Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363–372.
   PubMed Web of Science ®Google Scholar
• Freeman WR, Falkenstein I. Avastin and new treatments for AMD: Where are we? Retina. 2006;26:853–858.
   PubMed Web of Science ®Google Scholar
• Dano K, Andreasen PA, Grondahl-Hansen J, et al. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266.
   PubMed Web of Science ®Google Scholar
• Andreasen PA, Kjoller L, Christensen L, et al. The urokinase type plasminogen activator system in cancer metastasis: A review. Int J Cancer. 1997;72:1–22.
   PubMed Web of Science ®Google Scholar
• Dear AE, Medcalf RL. The urokinase-type-plasminogen activator receptor (CD87) is a pleiotropic molecule. Eur J Biochem. 1998;252:185–193.
   PubMedGoogle Scholar
• Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: Recent advances and implications for prognosis and therapy. Cancer Metastasis Rev. 2003;22:205–222.
   PubMed Web of Science ®Google Scholar
• Schmitt M, Wilhelm OG, Reuning U, et al. The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis Proteolysis. 2000;14:114–132.
   Google Scholar
• Blasi F, Carmeliet P. uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3:932–943.
   PubMed Web of Science ®Google Scholar
• Das A, McGuire PG, Eriqat C, et al. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci. 1999;40:809–813.
   PubMed Web of Science ®Google Scholar
• Behzadian MA, Windsor LJ, Ghaly N, et al. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J. 2003;17:752–754.
   PubMed Web of Science ®Google Scholar
• McGuire PG, Jones TR, Talarico N, et al. The urokinase/urokinase receptor system in retinal neovascularization: Inhibition by Å6 suggests a new therapeutic target. Invest Ophthalmol Vis Sci. 2003;44:2736–2742.
   PubMed Web of Science ®Google Scholar
• Rakic JM, Lambert V, Munaut C, et al. Mice without uPA, tPA,or plasminogen genes are resistant to experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:1732–1739.
   PubMed Web of Science ®Google Scholar
• Elner SG, Elner VM, Kindzelskii AL, et al. Human RPE cell lysis of extracellular matrix: Functional urokinase plasminogen activator receptor (uPAR), collagenase and elastase. Exp Eye Res. 2003;76: 585–595.
   PubMed Web of Science ®Google Scholar
• Das A, Boyd N, Jones TR, et al. Inhibition of choroidal neovascularization by a peptide inhibitor of the urokinase plasminogen activator and receptor system in a mouse model. Arch Ophthalmol. 2004;122:1844–1849.
   PubMed Web of Science ®Google Scholar
• Koh HJ, Bessho K, Cheng L, et al. Inhibition of choroidal neovascularization in rats by the urokinase-derived peptide Å6. Invest Ophthalmol Vis Sci. 2004;45:635–640.
   PubMed Web of Science ®Google Scholar
• Koh HJ, Freeman WR, Azen SP, et al. Effect of a novel octapeptide urokinase fragment, Å6, on experimental choroidal neovascularization in the monkey. Retina. 2006;26:202–209.
   PubMed Web of Science ®Google Scholar
• Colombo ES, Menicucci G, McGuire PG, et al. Hepatocyte growth factor/scatter factor promotes retinal angiogenesis through increased urokinase expression. Invest Ophthalmol Vis Sci. 2007;48:1793–1800.
   PubMed Web of Science ®Google Scholar
• Navaratna D, Menicucci G, Maestas J, et al. A peptide inhibitor of the urokinase/urokinase receptor system inhibits alteration of the blood-retinal barrier in diabetes. FASEB J. 2008;22:3310–3317.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Gotoh J, Fujie M, et al. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int J Cancer. 1994;57:727–733.
   PubMed Web of Science ®Google Scholar
• Min HY, Doyle LV, Vitt CR, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 1996;56:2428–2433.
   PubMed Web of Science ®Google Scholar
• Tressler RJ, Pitot PA, Stratton JR, et al. Urokinase receptor antagonists: Discovery and application to in vivo models of tumor growth. APMIS. 1999;107:168–173.
   PubMed Web of Science ®Google Scholar
• Le Gat L, Gogat K, Bouquet C, et al. In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathy. Gene Ther. 2003;10:2098–2103.
   PubMed Web of Science ®Google Scholar
• Jones TR, Haney, DN, Varga J, et al. Cyclic peptide ligands that target urokinase plasminogen activator receptor. US Patent Application 20040204348, October 14, 2004. Retrieved August 8, 2009 from www.uspto.gov.
   Google Scholar
• Koh HJ, Cheng L, Bessho K, et al. Intraocular properties of urokinase-derived antiangiogenic Å6 peptide in rabbits. J Ocul Pharmacol Ther. 2004;20:439–449.
   PubMed Web of Science ®Google Scholar
• Cheng L, Hostetler KY, Lee J, et al. Characterization of a novel intraocular drug-delivery system using crystalline lipid antivial prodrugs of ganciclovir and cyclic cidofovir. Invest Ophthalmol Vis Sci. 2004;45:4138–4144.
   PubMed Web of Science ®Google Scholar
• Cheng L, Hostetler KY, Chaidhawangul S, et al. Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-O-hexadecylpropanediol-3-phospho-ganciclovir. Invest Ophthalmol Vis Sci. 2002;43:515–521.
   PubMed Web of Science ®Google Scholar
• Lu S, Cheng L, Hostetler KY, et al. Intraocular properties of hexadecyloxypropyl-cyclic-cidofovir in Guinea pigs. J Ocul Pharmacol Ther. 2005;21:205–209.
   PubMed Web of Science ®Google Scholar